<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>SHILPAMED</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">SHILPAMED</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="shilpa-medicare-limited" class="section level1">
<h1>Shilpa Medicare Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SHILPAMED.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SHILPAMED.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SHILPAMED.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SHILPAMED.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SHILPAMED.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SHILPAMED.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SHILPAMED.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SHILPAMED.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SHILPAMED.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-11-27 </em></p>
<div id="shilpa-medicare-limited-shilpamed-analysis-headwinds-tailwinds-growth-prospects-and-key-risks" class="section level3">
<h3>Shilpa Medicare Limited (SHILPAMED) Analysis: Headwinds, Tailwinds, Growth Prospects, and Key Risks</h3>
<p>Shilpa Medicare Limited (SHILPAMED), an integrated pharma player focused on APIs, formulations, biologics, and CDMO, reported robust Q2 &amp; H1 FY26 results (ended Sep 30, 2025). Consolidated revenue grew 8% YoY to INR 700 cr (highest quarterly revenue INR 372 cr, +7% YoY), EBITDA +20% YoY to INR 208 cr (30% margin, up 300 bps), and PAT INR 91 cr (+184% YoY, surpassing FY25 full-year PAT of INR 78 cr). API (56% revenue) and formulations (34%) drove growth, with biologics at 9%. ROCE improved to ~17% (ex-biologics/NBE investments). However, recent USFDA inspection at Unit IV (Jadcherla) issued Form 483 with 8 observations (no repeats; &lt;1% US sales exposure). Below is a structured analysis based on the earnings transcript, financials, investor presentation, USFDA notice, and other disclosures.</p>
<div id="tailwinds-positive-catalysts" class="section level6">
<h6><strong>Tailwinds (Positive Catalysts)</strong></h6>
<ul>
<li><strong>Strong Financial Momentum &amp; Margin Expansion</strong>: Highest-ever quarterly EBITDA (INR 110 cr, 30% margin, +400 bps YoY). Gross margins at 74% (H1, +700 bps) driven by complex product mix (oncology, peptides, 505(b)(2)). Base formulations business +60-67% YoY ex-licensing; API +19% YoY. Declining interest costs and internal funding for capex support profitability.</li>
<li><strong>Product Launches &amp; Market Share Gains</strong>: NorUDCA (first-in-class NAFLD therapy) launching Q3 FY26 in India via 3 partners + own brand (Noduca™); targets 10-20% NAFLD treated population. US 505(b)(2) launches (Pemetrexed, Bortezomib) gaining share; Europe Nilotinib growing QoQ with limited competition.</li>
<li><strong>Robust Pipeline &amp; Diversification</strong>:
<ul>
<li>API: Semaglutide PV in Q4 FY26 (filing FY27), polymers/CDMO traction (OLC block commissioning Q3 FY26).</li>
<li>Formulations: 5+ 505(b)(2)/NDDS (e.g., Ondansetron ER Phase 3 done, launch FY27); 36 new approvals in H1 FY26.</li>
<li>Biologics: 8 biosimilars (Aflibercept Phase 3, Nivolumab Phase 1/3 Q4 FY26); 2 NBEs to Phase 1 FY27; rHA Phase 3 India/EU Q4 FY26 (Orion partnership).</li>
<li>CDMO: 25+ programs; integrated offerings (small molecule to ADC).</li>
</ul></li>
<li><strong>Regulatory Approvals &amp; Capacity</strong>: 500+ global filings; expanded capacities (UDCA, Tranexamic Acid) nearing full utilization. Multi-regulator approvals (USFDA, EMA, etc.) across sites.</li>
<li><strong>Strategic Moves</strong>: JV for Rivaroxaban ODF; peptide/polymer expansions; improving ROCE/debt metrics (net debt/EBITDA 1.4x).</li>
</ul>
</div>
<div id="headwinds-challenges" class="section level6">
<h6><strong>Headwinds (Challenges)</strong></h6>
<ul>
<li><strong>Regulatory Scrutiny</strong>: USFDA inspection (Nov 21, 2025) at Unit IV (Jadcherla, steriles/injectables) ended with Form 483 (8 observations, none repeat). Facility has EMA/Health Canada approvals but low US reliance (&lt;1% H1 FY26 sales, &lt;5% FY25). Response due soon; potential delays if escalated.</li>
<li><strong>Subsidiary Impairments</strong>: Ongoing exceptional losses (H1 FY26: INR 67 cr standalone) from Koanna entities (Canada/UK/Austria/UAE) and Indo Biotech (Malaysia) due to loan/investment impairments (e.g., interest accrual, forex gains). Signals weak foreign ops performance.</li>
<li><strong>Lumpy Income &amp; Mix Shift</strong>: Licensing/service income down YoY (H1: INR 129 cr vs. INR 165 cr); converting to supplies/profit-share but volatile. Lower CDMO/licensing contribution pressured margins earlier.</li>
<li><strong>High Capex &amp; Utilization</strong>: INR 153 cr capex in H1 FY26 (total FY26 ~INR 75-100 cr more); focus on peptides/OLC/Albumin. Underutilized assets (biologics/NDDS) delay leverage.</li>
<li><strong>Macro Pressures</strong>: Rising costs (RM, compliance, R&amp;D); US tariffs on 505(b)(2) mitigated via US CMOs, but Europe oncology competition intense.</li>
</ul>
</div>
<div id="growth-prospects" class="section level6">
<h6><strong>Growth Prospects</strong></h6>
<ul>
<li><strong>Short-Term (FY26-27)</strong>: NorUDCA ramp-up (sizable India NAFLD market); OLC commercialization (FY27, dedicated block); Semaglutide filing (captive formulations); 2-3 complex FDF launches (US/EU). API double-digit growth; formulations base business scaling. Expect sustained 30% EBITDA margins.</li>
<li><strong>Medium-Term (FY27+)</strong>: Biosimilars launches (Aflibercept FY27); rHA therapeutic/non-therapeutic (Orion EU deal); ADC/NBE Phase 1; peptide/polymer expansions. CDMO RFQs rising; integrated API-FDF-biologics positioning for global partnerships.</li>
<li><strong>Long-Term</strong>: Monetize investments (transdermals, fermentation); target higher ROCE via utilization. NAFLD/NASH global push for NorUDCA; GLP-1/ADC leadership. Potential: API/FDF to drive 15-20% CAGR; biologics/CDMO to contribute 20%+ revenue.</li>
<li><strong>Quantitative Outlook</strong>: H1 PAT already &gt; FY25; pipeline (8 biosimilars, 5+ NDDS, 25+ CDMO) supports multi-year growth. Investor deck projects operating leverage from underutilized assets.</li>
</ul>
</div>
<div id="key-risks" class="section level6">
<h6><strong>Key Risks</strong></h6>
<table>
<colgroup>
<col width="33%" />
<col width="33%" />
<col width="33%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Risk Category</strong></th>
<th><strong>Description</strong></th>
<th><strong>Mitigants</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Regulatory</strong></td>
<td>USFDA observations could lead to import alert/warning letter (though low US exposure). Pipeline delays (e.g., OLC CRL due to 3rd-party CMC).</td>
<td>Multi-regulator approvals; quick responses; low US reliance (&lt;5%).</td>
</tr>
<tr class="even">
<td><strong>Execution/Commercial</strong></td>
<td>Pipeline commercialization risks (clinical failures, partner delays e.g., Unicycive OLC FY27). Lumpy licensing → supply conversion volatility.</td>
<td>Diversified pipeline (50+ countries); captive integration; strong R&amp;D (400+ personnel).</td>
</tr>
<tr class="odd">
<td><strong>Financial</strong></td>
<td>High capex (INR 250+ cr FY26) amid INR 569 cr net debt; forex/RM inflation. Subsidiary losses (Koanna impairments).</td>
<td>Internal accruals funding; stable interest run-rate; improving ROCE/debt metrics.</td>
</tr>
<tr class="even">
<td><strong>Market/Competition</strong></td>
<td>Intense generics competition (Europe oncology); pricing erosion (Semaglutide late entry). NAFLD adoption risks.</td>
<td>Focus on complex/differentiated (505(b)(2), NCEs, NDDS); limited-competition launches.</td>
</tr>
<tr class="odd">
<td><strong>Operational</strong></td>
<td>Capacity underutilization; supply chain (tariffs, shortages). Geopolitical (foreign subs).</td>
<td>Backward integration; expansions; JV/partners.</td>
</tr>
</tbody>
</table>
</div>
<div id="overall-summary" class="section level6">
<h6><strong>Overall Summary</strong></h6>
<p><strong>Bullish Outlook with Managed Risks</strong>: SHILPAMED is in a strong growth phase, with H1 FY26 results showcasing execution (revenue/EBITDA beats, margin expansion) and a de-risked pipeline (NorUDCA, biosimilars, CDMO). Tailwinds from complex products, launches, and leverage outweigh headwinds like USFDA observations (low impact) and impairments (non-core). Growth prospects are compelling (15-20% CAGR potential via biologics/NDDS/CDMO), positioning it as an integrated innovator. <strong>Key Monitor</strong>: USFDA response and NorUDCA traction. <strong>Recommendation</strong>: Positive; accumulate on dips for long-term compounding (target FY26 revenue ~INR 1,500 cr+). Valuation likely supported by improving ROCE (17%) and pipeline milestones.</p>
<p><em>Analysis based solely on provided documents; market data as of Nov 2025 disclosures.</em></p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
